Chronic Myelogenous Leukemia

O’Brien, Susan; Berman, Ellin; Borghaei, Hossein; Dj, Doyle; Mp, Devetten; Devine, Steven M.; Hp, Erba; Gotlib, Jason; Jagasia, Madan; Je, Moore; Mughal, Tariq I.; Pinilla‐Ibarz, Javier; Radich, JP; Md, Shah; Pj, Shami; Bd, Smith; Ds, Snyder; Ms, Tallman; Talpaz, Moshe; Wetzler, Meir

doi:10.6004/jnccn.2009.0065

Cited by 103 publications

(14 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the stage of severe CML (accelerate and blast phases), prescribing higher doses of imatinib would cause more adverse effects and poor adherence [35]. For patients with multiple co-morbidities, adherence might be reduced due to adverse effects, drug–drug interaction or polypharmacy.…”

Section: Discussionmentioning

confidence: 99%

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients

Chen

Huang

et al. 2013

Int J Clin Pharm

View full text Add to dashboard Cite

Background The launch of imatinib has turned chronic myeloid leukaemia (CML) into a chronic illness due to the dramatic improvement in survival. Several recent studies have demonstrated that poor adherence to imatinib may hamper the therapeutic outcomes and result in increased medical expenditures, whilst research on exploring the reasons for non-adherence to imatinib is still limited. Objective This study aimed to explore the experience of patients as they journey through their CML treatments and associated imatinib utilisation in order to understand the perceptions, attitudes and concerns that may influence adherence to imatinib treatment. Setting This study was conducted at oncology outpatient clinics in a medical centre in southern Taiwan. Methods CML patients who regularly attended the oncology outpatient clinics to receive imatinib treatment from October 2011 to March 2012 were invited to participate in the study. Semi-structured face-to-face interviews were used to explore patients’ experiences and views of their treatment, their current CML status and CML-related health conditions, their concerns about imatinib treatment and imatinib-taking behaviours. Patient interviews were recorded, transcribed verbatim and thematically analysed using the constant comparison approach. Main outcome measure Themes related to patients’ views of the disease and health conditions, worries and concerns influencing imatinib utilisation behaviours are reported. Results Forty-two CML patients participated in the interviews. The emerging themes included: acceptance of current disease and health status, misconceptions about disease progression, factors associated with adherence to imatinib, concerns and management of adverse drug effects. Participants regarded CML as a chronic disease but had misconceptions about disease progression, therapeutic monitoring, resistance to imatinib and symptoms of side effects. Participants were generally adherent to imatinib and favoured long-term prescriptions to avoid regular outpatient visits for medication refills. Experiencing adverse effect was the main reason influencing adherence and led to polypharmacy. Most participants altered medicine-taking behaviours to maintain long-term use of imatinib. Conclusion Taiwanese CML patients are adherent to imatinib but report changing their medication-taking behaviour due to adverse drug effects and associated polypharmacy. Patients’ misconceptions of the disease and medication suggests that it is necessary to improve communication between patients and healthcare professionals. Routinely providing updated information as part of the patient counselling process should be considered as a means of improving this communication.

show abstract

Section: Discussionmentioning

confidence: 99%

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients

Chen

Huang

et al. 2013

Int J Clin Pharm

View full text Add to dashboard Cite

show abstract

“…The criteria for monitoring patients receiving TKIs are summarized in the European LeukemiaNet and National Comprehensive Cancer Network guidelines. 10,11 The clinical significance of monitoring…”

Section: Monitoring Endpoints Correlate With Long-term Outcomesmentioning

confidence: 99%

“…The set guidelines of the European LeukemiaNet and the National Cancer Care Network suggest peripheral blood testing every 3 months for QPCR. 10,11 On a practical side, however, if a patient For personal use only. on June 19, 2019.…”

Section: Radich Blood 15 October 2009 ⅐ Volume 114 Number 16mentioning

confidence: 99%

How I monitor residual disease in chronic myeloid leukemia

Radich

2009

Blood

Self Cite

View full text Add to dashboard Cite

Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and "guidelines" using the molecular endpoints of CML has outpaced practice norms, commercial laboratory application, and reimbursement practices, leaving some anxiety (if not confusion and despair) about molecular monitoring in the day-to-day treatment of CML. This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic. (Blood. 2009;114: 3376-3381)

show abstract

“…Overexpression of BCR-ABL protein resulted in disregulation of Tyrosine Kinase (TK) activity and trigger leukemogenesis. 6,[9][10][11] Tyrosine Kinases are enzymes that play a role as mediator in the process of signal transduction for cell proliferation, differentiation migration, metabolism and apoptosis. 12,13 Chronic myelogenous leukemia is characterized by loss of control of the process of hematopoiesis leading to excessive proliferation and differentiation on myeloid elements at all stages of maturation.…”

Section: Introductionmentioning

confidence: 99%

Tyrosine Kinase level and White Blood Cells Count in Untreated and Treated Chronic Myelogenous Leukemia Patients with BCR ABL gene

2016

IJSR

View full text Add to dashboard Cite

Chronic Myelogenous Leukemia

Cited by 103 publications

References 95 publications

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients

How I monitor residual disease in chronic myeloid leukemia

Tyrosine Kinase level and White Blood Cells Count in Untreated and Treated Chronic Myelogenous Leukemia Patients with BCR ABL gene

Contact Info

Product

Resources

About